Management of Loculated Pleural Effusions
Transthoracic ultrasound-guided drainage with intrapleural fibrinolytic therapy is the first-line approach for managing loculated pleural effusions, followed by definitive management based on the underlying etiology and lung expandability. 1
Diagnostic Approach
Imaging Selection
Transthoracic ultrasound (TUS) is the preferred initial imaging modality:
CT scanning with contrast enhancement should be used when:
Diagnostic Procedures
- Perform ultrasound-guided thoracentesis for initial diagnosis 1
- Send pleural fluid for:
- Biochemical analysis (pH, glucose, LDH)
- Cytology
- Microbiology (including TB culture) 2
- Always send pleural tissue for TB culture when biopsy is performed 2
Management Algorithm
Step 1: Initial Assessment
- Evaluate effusion size and symptoms
- Determine underlying etiology (malignant vs. non-malignant)
- Assess lung expandability with large-volume thoracentesis 1
Step 2: Drainage Approach
- For all loculated effusions: Use ultrasound guidance for drainage 1
- If drainage is inadequate due to loculations, proceed to intrapleural fibrinolytic therapy:
- Urokinase: 100,000 IU daily for 3 days, or
- Streptokinase: 250,000 IU twice daily for three doses 1
Step 3: Definitive Management Based on Etiology
For Malignant Loculated Effusions:
If lung is expandable after drainage/fibrinolytics:
If lung is trapped or pleurodesis fails:
For Non-malignant Loculated Effusions:
- Treat underlying cause with appropriate therapy
- For complicated parapneumonic effusions:
- Continue intrapleural fibrinolytics until adequate drainage 3
- Consider antibiotics if infected
Step 4: For Refractory Cases
- Multiple loculations not responding to fibrinolytics: Consider thoracoscopy 1
- Persistent trapped lung: Surgical decortication may be necessary 4
- Failed medical management: Video-assisted thoracoscopic surgery (VATS) to break up loculations and release adhesions 2
Efficacy and Outcomes
- Intrapleural fibrinolytics can increase drainage volumes and improve radiological appearance in 60-100% of cases 1
- Urokinase can result in >2/3 reduction in effusion size in 72.2% of patients with malignant loculated effusions 1
- Streptokinase has shown radiographic improvement and symptom amelioration in studies of multiloculated malignant effusions 2
Important Considerations
- Timing is critical: Delayed treatment of loculated effusions leads to longer hospital stays and more complicated courses 1
- Safety profile: While generally well-tolerated, fibrinolytic agents should be used with caution, with careful consideration of risk/benefit ratio for individual patients 2
- Specialist involvement: An appropriately experienced specialist should be involved in the care of all patients receiving fibrinolytic therapy 2
- Malignant effusions: Consider the patient's prognosis when selecting management approach; indwelling catheters may be preferable for shorter life expectancy to minimize hospitalization 2
By following this structured approach to loculated pleural effusions, clinicians can optimize drainage success and improve patient outcomes while minimizing complications and unnecessary procedures.